Dimethyl Fumarate (Tecfidera) pathway for Walton Centre MS patients
|
|
- Tamsin Baldwin
- 5 years ago
- Views:
Transcription
1 Dimethyl Fumarate (Tecfidera) pathway for Walton Centre MS patients Author and Contact details: Responsible Director: Ian Pomeroy Service lead for MS. Tel: (0151) Dr Enevoldson Approved by and date: Drug and Therapeutics Committee October 2014 Document Type: CLINICAL GUIDELINE Version 1.0 Scope: Document Approval, History/Changes All trust employees. For further information contact the Governance Department on Tel: (0151) Think of the environment Do you have to print this out this document? You can always view the most up to date version electronically on the Trust intranet. Page 1 of 10
2 Table of Contents 1. Pathway Initial appointment with Neurologist MS Nurse Clinic MS nurse follow up Appointment at 3 and 6 months Annual Neurologist Review Appendix Indications and Guidelines Licensed Indication NICE Guidelines Specialist Commissioning Guidelines Licensed Dose Mechanism of Action Effectiveness Contra Indications Cautions Side Effects Flushing Gastrointestinal Symptoms Infection Abnormal LFTs Renal Impairment Haematological Effects Interactions Vaccination Reproduction Issues Contraception Pregnancy Breast-feeding Switching Treatments Monitoring Pre treatment During treatment Page 2 of 10
3 1. Pathway 1.1. Initial appointment with Neurologist Neurologist will: Consider treatment options with the patient. If dimethyl fumarate is considered the neurologist should confirm eligibility according to current licensed indication, NICE guidelines and specialist commissioning guidelines. Review for presence of contraindications, consider interactions, and cautions. Information to Patient Discuss evidence base and potential benefits. Discuss potential side effects. Discuss Monitoring. For women of childbearing potential, discuss issues surrounding contraception, pregnancy and breast feeding, Agree stopping criteria. Following consideration, assessment and discussion as above, if patient and neurologist consider dimethyl fumarate treatment is appropriate the patient should be referred to the MS nurse with a letter confirming eligibility for treatment. Page 3 of 10
4 1.2. MS Nurse Clinic MS Nurse Will: Discuss with patient aims of treatment and side effects and check patient s understanding of these issues. Discuss side effect profile flushing, GI events (diarrhoea, nausea, abdominal pain), infections and abnormal haematological, renal and liver tests. Discuss common symptoms of infection which should be reported to a physician. Discuss issues surrounding flushing take with food, temporary aspirin treatment and temporary dose reduction where required. Make the patient aware of any signs that mean the should stop taking Tecfidera and call a doctor - patients receiving Dimethyl fumarate should be instructed to report symptoms of infections to their GP. Discuss need to consider suspending treatment with serious infections. Full discussion with women of child bearing age with regard to need for effective contraception. Counsel regarding risks of oral contraception failure if significant diarrhoea should occur. Discuss risks of teratogenicity and potential risk of breast feeding. Discuss if pregnancy suspected MS Consultant/MS Nurse should be informed and tecfidera should be suspended. Discuss need to avoid live vaccines. Discuss need for adherence daily to therapy. Discuss need for adherence to monitoring protocol. Arrange monitoring with pre-treatment FBC, U&E, LFT. Discuss stopping criteria. Discuss pack sizes with the patient (Tecfidera starter pack 120mg bd for 7 days, Tecfidera Standard Pack 240mg bd thereafter) Discuss delivery options (home delivery, Boots pharmacy collection, hospital pharmacy collection) Inform the patient they will receive a Tecfidera patient support pack from Alcura Ltd. Send registration form and prescription to Alcura (Signed copy to be faxed to: Alcura Ltd, Selborne House, Mill Lane, Alton, Hampshire,GU34 2QJ. Tel: Freephone: Fax: Original signed copy to be posted using pre-paid envelopes) Answer any questions from patient/family. Ensure contact details for MS Nurses given. Ensure 3 and 6 monthly MS Nurse appointment is made and patient has annual neurologist appointment. Letter to be sent to GP and Consultant to inform of response. Page 4 of 10
5 1.3. MS nurse follow up Appointment at 3 and 6 months MS nurse will Record any side effects of drug. Document any relapses. Inform GP and neurologist in writing of progress. Arrange monitoring tests with U&E, LFT, and FBC at 3 and 6 months Annual Neurologist Review Neurologist will: Document the patient s EDSS and any locally agreed objective measures. Review the number of relapses in the last 12 months. Document side effects and the patient s tolerance of dimethyl fumarate in the last 12 months. Record any changes of treatment. Ensure the patient has a 6 month follow up with MS Nurse and for 12 months with consultant. Arrange U&E, LFT and FBC at 12 months and decide on 6 monthly or 12 monthly ongoing monitoring as clinically indicated Page 5 of 10
6 2. Appendix Data predominately derived from Summary of product Characteristics: 2.1. Indications and Guidelines Licensed Indication Tecfidera is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis NICE Guidelines (TA320 Dimethyl fumarate is recommended as an option for treating adults with active relapsing-remitting multiple sclerosis (normally defined as 2 clinically significant relapses in the previous 2 years), only if: They do not have highly active or rapidly evolving severe relapsing-remitting multiple sclerosis, as defined by NICE and The manufacturer provides dimethyl fumarate with the discount agreed in the patient access scheme Specialist Commissioning Guidelines (SSC1451) All MS patients who meet the NICE criteria for dimethyl fumarate will receive funding from November Patients who start on dimethyl fumarate and progress and/or unable to continue will be eligible for other MS disease modifying treatments if they meet the criteria within either a published NICE Guidance and/or the NHS England Clinical Commissioning Policy: Disease Modifying Therapies for Patients with Multiple Sclerosis (MS) which can be found at: This will include fingolimod as a second line therapy Licensed Dose The starting dose is 120 mg twice a day for 7 days After 7 days, the dose is increased to the recommended dose of 240 mg twice a day Mechanism of Action The mechanism by which dimethyl fumarate exerts therapeutic effects in multiple sclerosis is not fully understood. Preclinical studies indicate that pharmacodynamic responses appear to be primarily mediated through activation of the Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) transcriptional pathway. Dimethyl fumarate has been shown to up regulate Nrf2-dependent antioxidant genes in patients (e.g. NAD(P)H dehydrogenase, quinone 1; [NQO1]) Effectiveness (Data from DEFINE and CONFIRM studies, - note CONFIRM included single blinded glatiramer acetate comparator group, both studies had placebo controlled groups and treatment groups Page 6 of 10
7 with dimethyl fumarate 240bd or 240tds, figures quoted below are 240mg bd group vs. placebo from both studies). Eligibility Criteria - EDSS 0-5, 1 relapse in 1year or MRI with 1 enhancing lesion 6 weeks prior to randomization. Baseline characteristics mean age 37-39y, annualized relapse rate mean disease duration y, mean EDSS Clinical Outcomes Relative reduction of 44-53% in annual relapse rate vs placebo Absolute reduction of relapses/year Relative reduction of 3 month sustained progression over 2 years of 17-38% (lower figure not significant) Absolute reduction of 3 month sustained progression over 2 years of 4-11% 2.5. Contra Indications Hypersensitivity 2.6. Cautions Patients with low lymphocyte counts Severe active gastrointestinal disease Severe renal impairment Severe hepatic impairment 2.7. Side Effects Flushing Experienced in 34% of trial patients vs. 4% of placebos. Can include hot flush, warmth, redness, itching and burning sensation. Flushing events tend to begin early in the course of treatment (primarily during the first month) and in patients who experience flushing, these events may continue to occur intermittently throughout treatment with dimethyl fumarate. In the majority of patients flushing was mild or moderate in severity, 3% of patients discontinued treatment due to flushing. 3/2560 trial patients experienced serious flushing thought to be hypersensitivity or anaphylactic reactions. Temporary dose reduction to 120 mg twice a day may reduce the occurrence of flushing and gastrointestinal adverse reactions. Within 1 month, the recommended dose of 240 mg twice a day should be resumed. Dimethyl Fumarate should be taken with food which may improve tolerability. Administration of 325 mg (or equivalent) non-enteric coated acetylsalicylic acid, 30 minutes prior to Dimethyl fumarate, over 4 days of dosing, did not alter the pharmacokinetic profile of Dimethyl fumarate and reduced the occurrence and severity of flushing in a healthy volunteer study. However, long term use of acetylsalicylic acid is not recommended for the management of flushing. Potential risks associated with acetylsalicylic acid therapy should be considered prior to co-administration with Dimethyl fumarate. Page 7 of 10
8 2.7.2 Gastrointestinal Symptoms The incidence of a variety of gastrointestinal events was higher in treated patients vs. placebo in the trials (diarrhoea 14% vs. 10%, nausea 12% vs.9%, upper abdominal pain 10% vs.6%, abdominal pain 9% vs.4%, vomiting 8% vs.5% and dyspepsia 5% vs.3%). Gastrointestinal events tend to begin early in the course of treatment (primarily during the first month) and in patients who experience gastrointestinal events, these events may continue to occur intermittently throughout treatment. In the majority of patients who experienced gastrointestinal events, symptoms were mild or moderate in severity. 4% of patients discontinued due to gastrointestinal events. The incidence of serious gastrointestinal events, including gastroenteritis and gastritis, was seen in 1% of patients treated with dimethyl fumarate Infection The incidence of infections (60% vs 58%) and serious infections (2% vs 2%) was similar in patients treated with dimethyl fumarate or placebo, respectively in phase 3 trials. There was no increased incidence of serious infections observed in patients with lymphocyte counts <0.8x109/L or <0.5x109/L. If a patient develops a serious infection, suspending treatment with dimethyl fumarate should be considered and the benefits and risks should be reassessed prior to re-initiation of therapy. Patients receiving dimethyl fumarate should be instructed to report symptoms of infections to a physician. Patients with serious infections should not start treatment with dimethyl fumarate until the infection(s) is resolved Abnormal LFTs The majority of patients with elevations had hepatic transaminases that were <3 times the upper limit of normal (ULN). The increased incidence in patients treated with Dimethyl fumarate relative to placebo was primarily seen during the first 6 months of treatment. Elevations of alanine aminotransferase and aspartate aminotransferase 3 times ULN, respectively, were seen in 5% and 2% of patients treated with placebo and 6% and 2% of patients treated with Dimethyl fumarate. There were no elevations in transaminases 3 times ULN with concomitant elevations in total bilirubin >2 times ULN. Discontinuations due to elevated hepatic transaminases were <1% and similar in patients treated with Dimethyl fumarate or placebo Renal Impairment In placebo-controlled studies, the incidence of proteinuria was higher in patients treated with dimethyl fumarate (9%) compared to placebo (7%). The overall incidence of renal and urinary adverse events was similar for dimethyl fumarate and placebo-treated patients. There were no reports of serious renal failure. On urinalysis, the percentage of patients with protein values of 1+ or greater was similar for Dimethyl fumarate (43%) and placebo-treated patients (40%). Typically, laboratory observations of proteinuria were not progressive. Compared to patients treated with placebo, estimated glomerular filtration rate was observed to increase in patients treated with Dimethyl fumarate, including those patients with 2 consecutive occurrences of proteinuria ( 1+). Page 8 of 10
9 2.7.6 Haematological Effects In the placebo-controlled studies, most patients (>98%) had normal lymphocyte values prior to initiating treatment. Upon treatment with Dimethyl fumarate, mean lymphocyte counts decreased over the first year by approximately 30% of baseline value with a subsequent plateau. Mean and median lymphocyte counts remained within normal limits. Lymphocyte counts <0.5x109/l were observed in <1% of patients treated with placebo and 6% of patients treated with Dimethyl fumarate. A lymphocyte count <0.2x109/l was observed in 1 patient treated with Dimethyl fumarate and in no patients treated with placebo. A transient increase in mean eosinophil counts was seen during the first 2 months of therapy Interactions During treatment with dimethyl fumarate, simultaneous use of other fumaric acid derivatives (topical or systemic) should be avoided. As of August 2014 there are no licensed fumaric acid derivatives available in the UK (a small number of dermatology patients may be taking Fumaderm for severe psoriasis). Concurrent therapy with nephrotoxic medicinal products (such as aminoglycosides, diuretics, NSAIDs or lithium) may increase the potential of renal adverse reactions (e.g. proteinuria) in patients taking dimethyl fumarate (see section 4.8) Vaccination Live vaccines might carry an increased risk of clinical infection and should not be given to patients treated with Dimethyl fumarate unless, in exceptional cases, this potential risk is considered to be outweighed by the risk to the individual of not vaccinating Reproduction Issues Contraception In vitro CYP induction studies did not demonstrate an interaction between dimethyl fumarate and oral contraceptives. In vivo interaction studies have not been performed with oral contraceptives. Even though an interaction is not expected, non-hormonal contraceptive measures should be considered with dimethyl fumarate Pregnancy There are no or limited amount of data from the use of dimethyl fumarate in pregnant women. Animal studies have shown reproductive toxicity. Dimethyl fumarate is not recommended during pregnancy and in women of childbearing potential not using appropriate contraception. Dimethyl fumarate should be used during pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the foetus Breast-feeding It is unknown whether dimethyl fumarate or its metabolites are excreted in human milk. A risk to the newborns/infants cannot be excluded. A decision must be made whether to discontinue breast-feeding or to discontinue dimethyl fumarate therapy. The benefit of breast-feeding for the child and the benefit of therapy for the woman should be taken into account Switching Treatments As of August 2014 Biogen state there is no known reason why patients cannot be directly switched from Tecfidera onto other DMFs without a washout period. Page 9 of 10
10 2.12. Monitoring Pre treatment FBC, U&E, LFT During treatment U&E, LFT after 3 months U&E, LFT, FBC after 6 months U&E, LFT and FBC repeated 6 to 12 months thereafter as clinically indicated. Page 10 of 10
Treatment monitoring protocol for Dimethyl fumarate therapy in active Relapsing Remitting Multiple Sclerosis
Treatment monitoring protocol for Dimethyl fumarate therapy in active Relapsing Remitting Multiple Sclerosis This protocol provides monitoring guidance for adult patients requiring Dimethyl fumarate therapy
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Tecfidera 120 mg gastro-resistant hard capsules 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each capsule contains 120 mg dimethyl
More informationTECFIDERA is indicated in patients with relapsing multiple sclerosis to reduce the frequency of relapses and to delay the progression of disability.
AUSTRALIAN PRODUCT INFORMATION TECFIDERA (dimethyl fumarate) modified release capsules 1 NAME OF THE MEDICINE Dimethyl fumarate (DMF). 2 QUALITATIVE AND QUANTITATIVE COMPOSITION TECFIDERA (dimethyl fumarate
More informationTECFIDERA PRODUCT MONOGRAPH. Dimethyl fumarate delayed-release capsules. 120 mg and 240 mg. Other Nervous System Drug
PRODUCT MONOGRAPH Pr TECFIDERA Dimethyl fumarate delayed-release capsules 120 mg and 240 mg Other Nervous System Drug Biogen Canada Inc. 90 Burnhamthorpe Road West, Suite 1100 Mississauga, Ontario L5B
More informationTreating MS patients earlier in the disease progression may affect long-term outcomes 1-4
Treating MS patients earlier in the disease progression may affect long-term outcomes 1-4 TIME DISEASE ONSET EARLY TREATMENT NATURAL COURSE OF MS LATER TREATMENT DISABILITY INCREASE The disease activity
More informationPrescribing Framework for Mycophenolate Mofetil or Mycophenolic Acid (Myfortic ) Post Solid Organ Transplant
Hull & East Riding Prescribing Committee Prescribing Framework for Mycophenolate Mofetil or Mycophenolic Acid (Myfortic ) Post Solid Organ Transplant Patient s Name:.. NHS Number: Patient s Address:...
More informationPrescribing Framework for Methotrexate for Immunosuppression in ADULTS
Hull & East Riding Prescribing Committee Prescribing Framework for Methotrexate for Immunosuppression in ADULTS Patient s Name:.. NHS Number: Patient s Address:... (Use addressograph sticker) GP s Name:...
More informationLocal Natalizumab Treatment Protocol
Local Natalizumab Treatment Protocol 1. New medicine name: Natalizumab 300mg concentrate for solution for infusion (Natalizumab ) 2. Licensed indication(s): Natalizumab is indicated for single disease
More informationAubagio. Aubagio (teriflunomide) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.60.09 Subject: Aubagio Page: 1 of 6 Last Review Date: June 22, 2017 Aubagio Description Aubagio (teriflunomide)
More informationHYDROXYCARBAMIDE for Haematological conditions (Adults)
Shared Care Guideline DRUG: Introduction: Contraindications & Warnings: HYDROXYCARBAMIDE for Haematological conditions (Adults) Indication: Hydroxycarbamide is an established treatment in haematological
More informationWestern Locality Shared care Information ~ Penicillamine, Rheumatology April 2013
Western Locality Shared care Information ~ Penicillamine, Rheumatology April 2013 Penicillamine Treatment of: Rheumatoid arthritis Specialist: Please complete the Shared Care letter sending a request to
More information. AREAS OF RESPONSIBILITY FOR SHARED CARE
SHARED CARE GUIDELINE FOR RILUZOLE IN THE MANAGEMENT OF MOTOR NEURONE DISEASE (MND) SPECIFICALLY AMYOTROPHIC LATERAL SCLEROSIS (ALS) INDICATION This shared care guideline has been prepared to support the
More informationDuration of treatment All DMARDs are long term treatments. Clinical benefit may take up to 6 months. 1
Leflunomide Traffic light classification- Amber 1 Information sheet for Primary Care Prescribers Part of the Shared Care Protocol: Management of Rheumatological Conditions with Disease-Modifying Anti Rheumatic
More informationSHARED CARE PRESCRIBING GUIDELINE
WORKING IN PARTNERSHIP East Surrey CCG, Guildford & Waverley CCG, North West Surrey CCG, Surrey Downs CCG, Surrey Heath CCG, North East Hampshire & Farnham CCG, Crawley CCG, Horsham & Mid-Sussex CCG SHARED
More informationMedicines Management Group
SHARED CARE PROTOCOL for FULVESTRANT (FASLODEX ) INJECTION Scope Fulvestrant may be considered for shared care arrangements for the treatment of metastatic breast cancer for disease relapse. Unique Identifier
More informationSULFASALAZINE (Adults)
Shared Care Guideline DRUG: Introduction: SULFASALAZINE (Adults) Indication: Disease modifying drug for rheumatoid arthritis, psoriatic arthritis, undifferentiated arthritis, spondyloarthropathies, Crohn
More informationSHARED CARE PRESCRIBING GUIDELINE
SHARED CARE PRESCRIBING GUIDELINE RILUZOLE for the Treatment of MOTOR NEURONE DISEASE NHS Surrey s Medicines Management Committee classification: Amber N.B. The eligibility criteria included here apply
More informationAubagio. Aubagio (teriflunomide) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.07.09 Subsection: Endocrine and Metabolic Drugs Original Policy Date: April 1, 2013 Subject: Aubagio
More informationBNSSG Shared Care Guidance Please complete all sections
NHS Bristol CCG NHS North Somerset CCG NHS South Gloucestershire CCG North Bristol NHS Trust University Hospitals Bristol NHS Foundation Trust Weston Area Health NHS Trust BNSSG Shared Care Guidance Please
More informationESCA: Cinacalcet (Mimpara )
ESCA: Cinacalcet (Mimpara ) Effective Shared Care Agreement for the Treatment of Primary hyperparathyroidism when parathyroidectomy is contraindicated or not clinically appropriate. Specialist details
More informationBortezomib, Thalidomide & Dexamethasone
DRUG ADMINISTRATION SCHEDULE Cumbria, Northumberland, Tyne & Wear Area Team Day Drug Dose Route Diluent Rate 1, 4, 8, & 11 2 Bortezomib 1.3mg/m IV bolus/ SC injection* None Fast bolus: 3 to 5 seconds 1
More informationPRESCRIBING GUIDANCE METHOTREXATE for the treatment of vasculitis
PRESCRIBING GUIDANCE METHOTREXATE for the treatment of vasculitis For the latest information on interactions and adverse effects, always consult the latest version of the Summary of Product Characteristics
More informationPrescribing Guidelines Prescribing arrangement for the management of patients transferring from Secondary Care to Primary Care
Berkshire West Integrated Care System Representing Berkshire West Clinical Commisioning Group Royal Berkshire NHS Foundation Trust Berkshire Healthcare NHS Foundation Trust Berkshire West Primary Care
More informationShared Care Guideline Riluzole Treatment of Motor Neurone Disease
North Central London Joint Formulary Committee Shared Care Guideline Riluzole Treatment of Motor Neurone Disease Dear GP This shared care agreement outlines suggested ways in which the responsibilities
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Tecfidera 120 mg gastro-resistant hard capsules Tecfidera 240 mg gastro-resistant hard capsules 2. QUALITATIVE AND QUANTITATIVE
More informationAxitinib (renal) Note: in some patients it may be appropriate to increase the dose to 6mg BD before increasing to 7mg BD.
Axitinib (renal) Indication Treatment of advanced renal cell carcinoma after failure of treatment with a first-line tyrosine kinase inhibitor (UK licensed indication states sunitinib) or a cytokine. (NICE
More informationName of Shared Care Agreement: AZATHIOPRINE/6-MERCAPTOPURINE: Oral immunomodulating drugs for inflammatory bowel disease. Reference number: 01/2008
Name of Shared Care Agreement: AZATHIOPRINE/6-MERCAPTOPURINE: Oral immunomodulating drugs for inflammatory bowel disease. Reference number: 01/2008 Shared care agreement has been developed appropriately
More informationPer Soelberg Sørensen
Per Soelberg Sørensen Danish Multiple Sclerosis Center Department of Neurology Rigshospitalet, University of Copenhagen Copenhagen, Denmark Declared receipt personal compensation for serving on scientific
More informationDegarelix Subcutaneous Injection (Firmagon ) Treatment Guideline
Mid Essex Locality Degarelix Subcutaneous Injection (Firmagon ) Treatment Guideline Contents FlowChart 2 Summary... 3 Key points... 3 Introduction... 3 Pharmacology... 3 Product information... 4 Place
More informationNHS Kent and Medway Medicines Management. Dronedarone (Multaq ) Shared Care Guideline For Prescribing
NHS Kent and Medway Medicines Management Dronedarone (Multaq ) Shared Care Guideline For Prescribing Issue No: 2 Review Date (If Applicable): Accountable Officer: Heather Lucas Contact Details: 01233 618158
More informationUnderstanding your Tecfidera. treatment. Information for patients who have been prescribed treatment with Tecfidera.
Understanding your Tecfidera treatment Information for patients who have been prescribed treatment with Tecfidera. Contents Treatment with Tecfidera About Multiple Sclerosis (MS) Multiple sclerosis A brief
More informationNCCP Chemotherapy Regimen. Olaparib Monotherapy
Olaparib INDICATIONS FOR USE: INDICATION ICD10 Regimen Code *Reimbursement Indicator Maintenance treatment of adult patients with platinum -sensitive relapsed BRCAmutated (germline and/or somatic) - high
More informationFulvestrant (Faslodex )
In Partnership with Health Authorities & GPs continuing-care guidelines Fulvestrant (Faslodex ) in the Management of Postmenopausal Women with Advanced Breast Cancer Approved by: Date approved: October
More informationPrescribing Framework for Mycophenolate Mofetil for Immunosuppression in ADULTs
Hull & East Riding Prescribing Committee Prescribing Framework for Mycophenolate Mofetil for Immunosuppression in ADULTs Patient s Name:.. NHS Number: Patient s Address:... (Use addressograph sticker)
More informationPrescribing Framework for Naltrexone in Relapse Prevention (Opioid Dependence)
Hull & East Riding Prescribing Committee Prescribing Framework for Naltrexone in Relapse Prevention (Opioid Dependence) Patients Name: Unit Number: Patients Address:.. G.P s Name:.. Communication We agree
More informationCardiff and Vale (C&V) UHB Corporate Medicines Management Group Shared Care Committee SHARED CARE
Cardiff and Vale (C&V) UHB Corporate Medicines Management Group Shared Care Committee SHARED CARE Drug: RILUZOLE Protocol number: CV 39 Indication: AMYOTROPHIC LATERAL SCLEROSIS (ALS) General Guidance
More informationHydroxychloroquine (Adults)
Shared Care Guideline DRUG: Introduction: Contraindications & Warnings: Hydroxychloroquine (Adults) Indication: Rheumatoid arthritis and inflammatory osteoarthritis, discoid and systemic lupus erythematosus,
More informationDenosumab for the treatment of osteoporosis in postmenopausal women at increased risk of fractures
APper apc15-0avgfh7 Shared Care Guideline Denosumab for the treatment of osteoporosis in postmenopausal women at increased risk of fractures For the latest information on interactions and adverse effects,
More informationNHS Suffolk Shared Care Guidelines for the Treatment of Rheumatoid Arthritis with LEFLUNOMIDE
Suffolk Drug & Therapeutics Committee NHS Suffolk Shared Care Guidelines for the Treatment of Rheumatoid Arthritis with LEFLUNOMIDE What is a shared care document? Suffolk D&T operates a traffic light
More informationFactsheet LINACLOTIDE (Constella ) Irritable Bowel Syndrome constipation predominant (IBS-C)
North Central London Joint Formulary Committee Factsheet LINACLOTIDE (Constella ) Irritable Bowel Syndrome constipation predominant (IBS-C) Start date: September 2018 Review date: September 2021 Document
More informationIt is also an option for those with Ph+ve CML who initially present in accelerated phase or with blast crisis 1.
Imatinib (Glivec ) Indications 1 Imatinib is recommended as first line treatment for people with Philadelphia chromosome positive (Ph+) chronic myeloid leukaemia (CML) in chronic phase 1. It is also an
More informationPEMBROLIZUMAB (KEYTRUDA ) for the treatment of advanced melanoma or previously treated NSCLC
DRUG ADMINISTRATION SCHEDULE Day Drug Dose Route Diluent Rate Day 1 Pembrolizumab 2mg/kg IV Infusion 100mL 0.9% Sodium Chloride* Or 100mL 5% Glucose* *Final concentration must be between 1 to 10mg/mL Over
More informationRegulatory Status FDA-approved indication: Tecfidera is indicated for the treatment of patients with relapsing forms of multiple sclerosis (1).
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.60.01 Subject: Tecfidera Page: 1 of 5 Last Review Date: December 2, 2016 Tecfidera Description Tecfidera
More informationPrescribing Guidelines Prescribing arrangement for the management of patients transferring from Secondary Care to Primary Care
Berkshire West Integrated Care System Representing Berkshire West Clinical Commisioning Group Royal Berkshire NHS Foundation Trust Berkshire Healthcare NHS Foundation Trust Berkshire West Primary Care
More informationDocetaxel + Nintedanib
Docetaxel + Nintedanib Available for Routine Use in Burton in-patient Derby in-patient Burton day-case Derby day-case Burton community Derby community Burton out-patient Derby out-patient Indication Second
More informationSUMMARY OF SHARED CARE PROTOCOL FOR MYCOPHENOLATE MOFETIL (MMF)
SUMMARY OF SHARED CARE PROTOCOL FOR MYCOPHENOLATE MOFETIL (MMF) Please refer to Chester Rheumatology shared care protocol for MMF and separate responsibilities document for full details. Responsibilities
More informationCurrent Enrolling Clinical Trials
ASSESS RRMS patients with active disease who are still able to walk. Mariko Kita MD Description of Study/Trial: A 12-month, randomized, rater- and dose-blinded study to compare the efficacy and safety
More informationCommittee Approval Date: December 12, 2014 Next Review Date: December 2015
Medication Policy Manual Policy No: dru283 Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012 Committee Approval Date: December 12, 2014 Next Review Date: December 2015 Effective Date: January
More informationTrust-wide Guideline
Trust-wide Guideline For Shared Care Guidelines for the Use of Leflunomide (Arava ) A guideline recommended for use In: East and North Herts NHS Trust (ENHT) East and North Herts PCT/ENHCCG By: Consultants
More informationMedication Policy Manual. Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012
Medication Policy Manual Policy No: dru283 Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012 Committee Approval Date: December 16, 2016 Next Review Date: December 2017 Effective Date: January
More informationKELFER Deferiprone. COMPOSITION KELFER-250 Capsules Each capsule contains Deferiprone 250 mg
KELFER Deferiprone COMPOSITION KELFER-250 Capsules Each capsule contains Deferiprone 250 mg KELFER-500 Capsules Each capsule contains Deferiprone 500 mg DOSAGE FORM Capsules PHARMACOLOGY Pharmacodynamics
More informationAbiraterone Acetate is an antiandrogen used in the treatment of Castration-Resistant Prostate Cancer(CRPC).
For the use only of an Oncologist or a Hospital or a Laboratory ABIRATERONE ACETATE TABLETS Zabiteron-250 COMPOSITION Abiraterone Acetate Tablets 250mg Each uncoated tablets contains: Abiraterone Acetate
More informationDenosumab (Prolia 60 mg) Effective Shared Care Agreement For the treatment of Osteoporosis. Date: Date:
Denosumab (Prolia 60 mg) Effective Shared Care Agreement For the treatment of Osteoporosis Section 1: Shared care arrangements and responsibilities Section 1.1 Agreement for transfer of prescribing to
More informationCiclosporin 25mg, 50mg, 100mg capsules Ciclosporin oral solution 100mg/ml
Shared Care Protocol Ciclosporin for the treatment of rheumatoid arthritis Name of drug, form and strength Background Ciclosporin 25mg, 50mg, 100mg capsules Ciclosporin oral solution 100mg/ml Ciclosporin
More informationDrafting a Coverage Authorization Request Letter
Drafting a Coverage Authorization Request Letter The following information is presented for informational purposes only and is not intended to provide reimbursement or legal advice. Laws, regulations,
More informationCarboplatin and Fluorouracil
Carboplatin and Fluorouracil Indication Palliative chemotherapy for recurrent or metastatic head and neck squamous cell cancer for patients where cisplatin and / or cetuximab are not appropriate. Performance
More informationCABAZITAXEL Prostate Cancer
Systemic Anti-Cancer Treatment Protocol CABAZITAXEL Prostate Cancer PROCTOCOL REF: MPHACABAZ (Version No: 1.0) Approved for use in: Cabazitaxel in combination with prednisolone is a treatment option for
More informationCarfilzomib and Dexamethasone (CarDex)
Carfilzomib and Dexamethasone (CarDex) Indication Relapsed multiple myeloma for patients who have had only one previous line of therapy (that did not include bortezomib). (NICE TA457) ICD-10 codes Codes
More informationINITIATING ORAL AUBAGIO (teriflunomide) THERAPY
FOR YOUR PATIENTS WITH RELAPSING FORMS OF MS INITIATING ORAL AUBAGIO (teriflunomide) THERAPY INDICATION AUBAGIO (teriflunomide) is indicated for the treatment of patients with relapsing forms of multiple
More informationAROMASIN 25mg (Tablets)
APPROVED PACKAGE INSERT AROMASIN SCHEDULING STATUS: S4 PROPRIETARY NAME AND DOSAGE FORM: AROMASIN 25mg (Tablets) COMPOSITION: Each sugar-coated tablet contains 25 mg exemestane. Preservative: methyl p-hydroxybenzoate
More informationTECFIDERA (dimethyl fumarate) delayed-release capsules, for oral use Initial U.S. Approval: 2013
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use TECFIDERA safely and effectively. See full prescribing information for TECFIDERA. TECFIDERA (dimethyl
More informationNHS LINCOLNSHIRE in association with UNITED LINCOLNSHIRE HOSPITALS TRUST
NHS LINCOLNSHIRE in association with UNITED LINCOLNSHIRE HOSPITALS TRUST SHARED CARE GUIDELINE: CINACALCET in the management of secondary hyperparathyroidism in adult patients with end-stage renal disease
More informationDERBY-BURTON LOCAL CANCER NETWORK FILENAME Lenalidomide_MDS.DOC CONTROLLED DOC NO: HCCPG B78 CSIS Regimen Name: LEN_MDS.
Lenalidomide Available for Routine Use in Burton in-patient N/A Derby in-patient Burton day-case Derby day-case Burton outreach chemotherapy clinic N/A Derby outreach chemotherapy clinic Burton out-patient
More informationLEFLUNOMIDE FOR USE IN RHEUMATOLOGY & PAEDIATRIC RHEUMATOLOGY Shared Care Protocol
Oxfordshire Clinical Commissioning Group LEFLUNOMIDE FOR USE IN RHEUMATOLOGY & PAEDIATRIC RHEUMATOLOGY Shared Care Protocol This protocol provides prescribing and monitoring guidance for leflunomide therapy.
More informationSHARED CARE AGREEMENT: METHOTREXATE S/C
NB: This document should be read in conjunction with the current Summary of Product Characteristics (SPC) and BSR Guideline for disease-modifying anti-rheumatic drug (DMARD) therapy (available at www.rheumatology.org.uk/resources/guidelines/bsr_guidelines.aspx
More informationKELFER Capsules (Deferiprone)
Published on: 22 Sep 2014 KELFER Capsules (Deferiprone) Composition KELFER-250 Capsules Each capsule contains Deferiprone 250 mg KELFER-500 Capsules Each capsule contains Deferiprone 500 mg Dosage Form
More informationMycophenolate Mofetil (MMF)
SCG: For Transplant patients The following guidelines are designed to provide information relating to mycophenolate mofetil and to outline the responsibilities of the primary and secondary care teams in
More informationPRESCRIBING GUIDANCE TACROLIMUS for the treatment of INFLAMATORY BOWEL DISEASE (IBD)
PRESCRIBING GUIDANCE TACROLIMUS for the treatment of INFLAMATORY BOWEL DISEASE (IBD) For the latest information on interactions and adverse effects, always consult the latest version of the Summary of
More informationSHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR OPIOID DEPENDENCE
SHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR OPIOID DEPENDENCE INDICATION Naltrexone is a pure opiate antagonist licensed as an adjunctive prophylactic therapy in the maintenance
More informationAzathioprine Shared Care Guideline for GPs
Indication: Azathioprine Shared Care Guideline for GPs Active rheumatoid arthritis and other types of inflammatory arthritis, systemic lupus erythematosus, dermatomyositis and polymyositis, vasculitis
More informationINTRODUCTION Indication and Licensing
City and Hackney Clinical Commissioning Group Homerton University Hospital Foundation Trust DRUG NAME: Apixaban (Eliquis ) Transfer of Care document Indication: Treatment of acute venous thromboembolism
More informationSkin Pathway Group Alemtuzumab in Cutaneous Lymphoma
Skin Pathway Group Alemtuzumab in Cutaneous Lymphoma Indication: Treatment of patients with Cutaneous Lymphoma (Unlicensed use) Disease control prior to Reduced Intensity Conditioning Stem Cell Transplant
More informationProducts available Methotrexate tablets 2.5mg ONLY (Methotrexate tablets 10mg are NOT recommended as per NPSA guidance 5 ).
Methotrexate Traffic light classification- Amber 1 Information sheet for Primary Care Prescribers Part of the Shared Care Protocol: Management of Rheumatological Conditions with Disease-Modifying Anti
More informationSOMATROPIN ( Genotropin, Humatrope, Norditropin,
Shared Care Guidelines DRUG: SOMATROPIN ( Genotropin, Humatrope, Norditropin, Saizen and Omnitrope ) (Adults) Introduction: Indication: Growth hormone deficiency in adults Dosage & administration: 150-300
More informationDocument Details. Ibuprofen 200mg tablets and Ibuprofen oral liquid 100mg in 5ml
Title Document Details Patient Group Direction (PGD) Ibuprofen 200mg tablets and Ibuprofen oral liquid 100mg in 5ml Trust Ref No 1445-36348 Local Ref (optional) Main points the document The treatment of
More informationAtezolizumab Non-small cell lung cancer
Systemic Anti Cancer Treatment Protocol Atezolizumab Non-small cell lung cancer PROTOCOL REF: MPHAATNSCLC (Version No: 1.0) Approved for use in: Locally advanced/metastatic non squamous or squamous non-small
More informationLung Pathway Group Erlotinib in Non-Small Cell Lung Cancer (NSCLC)
Lung Pathway Group Erlotinib in Non-Small Cell Lung Cancer (NSCLC) Indication: NICE TA258 NICE TA162 Locally advanced or metastatic NSCLC as a first line treatment option Positive test for epidermal growth
More informationLung Pathway Group Carboplatin & PO Vinorelbine in Non-Small Cell Lung Cancer (NSCLC)
Lung Pathway Group Carboplatin & PO Vinorelbine in Non-Small Cell Lung Cancer (NSCLC) Indication: First line in radical/induction treatment in locally advanced NSCLC First line palliative treatment in
More informationDrug Name: Lithium Clinical Indications: Treatment and prophylaxis of mania; bipolar disorder; augmentation therapy in treatment resistant depression
SHARED CARE PROTOCOL AND INFORMATION FOR GPS Drug Name: Lithium Clinical Indications: Treatment and prophylaxis of mania; bipolar disorder; augmentation therapy in treatment resistant depression Version:
More informationEXENATIDE (BYETTA ) PROTOCOL, 5mcg and 10mcg SC injection pre-filled pens
EXENATIDE (BYETTA ) PROTOCOL, 5mcg and 10mcg SC injection pre-filled pens This document should be read in conjunction with the current Summary of Product Characteristics http://www.medicines.org.uk 1.
More informationNECN CHEMOTHERAPY HANDBOOK PROTOCOL
Nivolumab (Opdivo ) for treatment of advanced melanoma and Renal Cell Cancer (Also advanced/ metastatic NSCLC EMAS patients only -Nov 2016) DRUG ADMINISTRATION SCHEDULE (SINGLE AGENT Day Drug Daily dose
More informationBexarotene for cutaneous T-cell lymphoma (CTCL) Information for patients
Bexarotene for cutaneous T-cell lymphoma (CTCL) Information for patients page 2 We have prescribed you the medicine bexarotene, also known as Targretin, for the treatment of your cutaneous T-cell lymphoma
More informationIpilimumab in Melanoma
Ipilimumab in Melanoma Indication: Advanced (unresectable or metastatic) melanoma in adults who have received prior therapy LCNDG criteria to be met: Histologically confirmed unresectable stage III or
More informationIpilimumab (skin) Indication Advanced (unresectable or metastatic) melanoma in patients who have received prior therapy.
Ipilimumab (skin) Indication Advanced (unresectable or metastatic) melanoma in patients who have received prior therapy. (NICE TA268) ICD-10 codes Codes prefixed with C43 Regimen details Day Drug Dose
More informationNDMP Multiple Sclerosis Treatment Protocol. Alemtuzumab THERAPY
Alemtuzumab THERAPY INDICATIONS FOR USE: INDICATION Treatment of adult patients with relapsing remitting multiple sclerosis (RRMS) with active disease defined by clinical or imaging features ICD10 G35
More informationEFFECTIVE SHARE CARE AGREEMENT. FOR THE off license use of GLP1 mimetics in combination with insulin IN DUDLEY
Specialist details Patient identifier Name Tel: EFFECTIVE SHARE CARE AGREEMENT FOR THE off license use of GLP1 mimetics in combination with insulin IN DUDLEY The aim of Effective Shared Care Guidelines
More informationShared Care Guideline: Leflunomide
Basingstoke, Winchester & Southampton District Prescribing Committee Shared Care Guideline: Leflunomide Name of patient treated under this guideline: This shared care guideline has been produced to support
More informationSHARED CARE PRESCRIBING GUIDELINE LEFLUNOMIDE IN ADULT PATIENTS WITH RHEUMATOID ARTHRITIS DOCUMENT DETAILS
SHARED CARE PRESCRIBING GUIDELINE LEFLUNOMIDE IN ADULT PATIENTS WITH RHEUMATOID ARTHRITIS DOCUMENT DETAILS Document type Shared Care Prescribing Guideline Document name Shared Care Prescribing Guideline:
More informationALL Phase 2 Induction (25-60 years)
ALL Phase 2 (25-60 years) INDICATION of remission in Adult Acute Lymphoblastic Leukaemia (ALL) patients This protocol is suitable for patients aged 25-60 years. It may sometimes be used in older patients
More informationLACIPIL QUALITATIVE AND QUANTITATIVE COMPOSITION
LACIPIL lacidipine QUALITATIVE AND QUANTITATIVE COMPOSITION Lacidipine, 2 mg - round shaped white engraved on one face. Lacidipine, 4 mg - oval white with break line on both faces. Lacidipine, 6 mg - oval
More informationNCCP Chemotherapy Regimen. Alectinib Monotherapy
INDICATIONS FOR USE: Alectinib INDICATION ICD10 Regimen Code *Reimbursement Indicator Treatment of adult patients with anaplastic lymphoma kinase (ALK)- positive advanced non-small cell lung cancer (NSCLC)
More informationLung Pathway Group Cisplatin & PO Vinorelbine in Non- Small Cell Lung Cancer (NSCLC)
Lung Pathway Group Cisplatin & PO Vinorelbine in Non- Small Cell Lung Cancer (NSCLC) Indication: First line in radical/induction treatment in locally advanced NSCLC First line palliative treatment in advanced/metastatic
More informationPrescribing Guidelines Prescribing arrangement for the management of patients transferring from Secondary Care to Primary Care
Berkshire West Integrated Care System Representing Berkshire West Clinical Commisioning Group Royal Berkshire NHS Foundation Trust Berkshire Healthcare NHS Foundation Trust Berkshire West Primary Care
More informationShared Care Protocol for the Prescription and Supply of Low Molecular Weight Heparins
Tameside Hospital NHS Foundation Trust and NHS Tameside and Glossop Shared Care Protocol for the Prescription and Supply of Low Molecular Weight Heparins Version 5.2 Version: 5.2 Authorised by: Joint Medicines
More informationObjectives. There Aren t Enough Hours in the Day
There Aren t Enough Hours in the Day Medication monitoring and communication of results Objectives Review the types of testing being ordered on patients receiving therapies other than platforms Discuss
More informationNORTH AND EAST DEVON HEALTHCARE COMMUNITY SHARED CARE PRESCRIBING GUIDELINE
NORTH AND EAST DEVON HEALTHCARE COMMUNITY SHARED CARE PRESCRIBING GUIDELINE http://www.devonpct.nhs.uk/treatments/ne_devon_shared_care_guidelines.aspx#a Azathioprine Treatment of rheumatological conditions
More informationWARNING: RISK OF SERIOUS INFECTIONS
RA PROGRESSION INTERRUPTED 1 DOSAGE AND ADMINISTRATION GUIDE No structural damage progression was observed at week 52 in 55.6% and in 47.8% of patients receiving KEVZARA 200 mg + MTX or 150 mg + MTX, compared
More informationSHARED CARE GUIDELINE
SHARED CARE GUIDELINE Drug: Methotrexate Introduction Indication: Licensed: Rheumatoid arthritis, severe psoriasis, severe active juvenile idiopathic arthritis, severe psoriatic arthritis, mild to moderate
More informationPanobinostat, Bortezomib and Dexamethasone
Panobinostat, Bortezomib and Dexamethasone Indication Treatment of relapsed/refractory multiple myeloma in patients who have received at least 2 prior regimens, including bortezomib and an immunomodulatory
More information